- Home
- BFIN vs VTYX Comparison
BFIN vs VTYX Comparison
Compare BFIN & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFIN
- VTYX
- Stock Information
- Founded
- BFIN 1924
- VTYX 2018
- Country
- BFIN United States
- VTYX United States
- Employees
- BFIN N/A
- VTYX N/A
- Industry
- BFIN Savings Institutions
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- BFIN Finance
- VTYX Health Care
- Exchange
- BFIN Nasdaq
- VTYX Nasdaq
- Market Cap
- BFIN 164.7M
- VTYX 154.9M
- IPO Year
- BFIN N/A
- VTYX 2021
- Fundamental
- Price
- BFIN $12.66
- VTYX $1.39
- Analyst Decision
- BFIN
- VTYX Buy
- Analyst Count
- BFIN 0
- VTYX 4
- Target Price
- BFIN N/A
- VTYX $11.33
- AVG Volume (30 Days)
- BFIN 13.7K
- VTYX 818.0K
- Earning Date
- BFIN 05-08-2025
- VTYX 02-27-2025
- Dividend Yield
- BFIN 3.17%
- VTYX N/A
- EPS Growth
- BFIN N/A
- VTYX N/A
- EPS
- BFIN 0.33
- VTYX N/A
- Revenue
- BFIN $49,205,000.00
- VTYX N/A
- Revenue This Year
- BFIN $2.15
- VTYX N/A
- Revenue Next Year
- BFIN $8.53
- VTYX N/A
- P/E Ratio
- BFIN $38.18
- VTYX N/A
- Revenue Growth
- BFIN N/A
- VTYX N/A
- 52 Week Low
- BFIN $9.60
- VTYX $1.34
- 52 Week High
- BFIN $13.97
- VTYX $8.48
- Technical
- Relative Strength Index (RSI)
- BFIN 46.36
- VTYX 35.26
- Support Level
- BFIN $12.28
- VTYX $1.34
- Resistance Level
- BFIN $13.04
- VTYX $1.50
- Average True Range (ATR)
- BFIN 0.38
- VTYX 0.12
- MACD
- BFIN -0.05
- VTYX 0.01
- Stochastic Oscillator
- BFIN 29.23
- VTYX 16.23
About BFIN BankFinancial Corporation
BankFinancial Corp is a national bank principally engaged in the business of commercial, family and personal banking. It offers customers a broad range of loan, deposit, trust and other financial products and services. The Bank offers customers a broad range of loan, deposit, trust and other financial products and services through all full-service banking offices located in Cook, DuPage, Lake and Will Counties, Illinois and through Internet Branch.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.